Fernando Albericio
Professor
University of KwaZulu-Natal, University of Barcelona
Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Alexander Pisarchik
Director of Protein Engineering
Alcamena Stem Cell therapeutics, LLC
Jari Willems
Chemical Scientist
Endoprotease Services BV
Ishita Shah
CEO
Matrubials, Inc.
Jeff Posakony
Director of Translational Chemistry
AltPep Corporation
Karsten Eastman
CEO, Post-doctoral Scholar
Sethera, University of Utah
Rick Ewing
VP, Head of Chemistry
Rapafusyn
Fa Liu
Chief Scientific Officer
Full-Life Technologies
Hans Melo
CEO
Menten AI, Inc.
Updates on clinical development of peptide therapeutics.
Masahiro Kojima
Researcher
Chugai Pharmaceutical Co., Ltd.
John Mumm
President & CEO
Deka Biosciences Inc
Mridula Dogra
Sr. Advisor-ADME Project Leadership
Eli Lilly and Company
Abi Vainstein Haras
Chief Medical Officer
Sapience Therapeutics, Inc.
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies.
Christine Beeton
Professor
Baylor College of Medicine
David Guay
VP Innovation and Technology
Feldan Therapeutics
Markus Muttenthaler
Professor in Medicinal and Biological Chemistry
The University of Queensland
Thomas Von Erlach
CSO
Vivtex
This year's Spotlight on Discovery is focused on peptide use in alcohol & drug addiction research.
Jane Aldrich
Professor
University of Florida
Jean Bidlack
Professor of Pharmacology and Physiology
University of Rochester School of Medicine and Dentistry
Joseph Schacht
Associate Professor
University of Colorado School of Medicine
Bach-Ngan Wetzel
Postdoctoral Researcher
Numaferm GmbH
Maciej Walczak
Associate Professor
University of Colorado
Michael Kopach
Associate Vice President
Eli Lilly and Company
Alicia Engelbrecht
Post Doc Process Science, Project Lead
Boehringer Ingelheim RCV GmbH & Co KG.
Lenka Žáková
Scientist
Institute of Organic Chemistry and Biochemistry of the CAS
This panel on diversity in clinical trials explored the vital role that diverse populations play in advancing medical research and improving health outcomes. Experts discussed the benefits of diverse trials, such as improved drug efficacy across different populations and better safety profiles alongside strategies for overcoming barriers to participation, ensuring inclusive recruitment practices, and fostering trust within underrepresented communities. The session highlighted real-world examples and provided actionable steps to make clinical trials more equitable and representative.
This panel discussion looked at the use of peptides outside of the traditional pharmaceutical landscape. This provided an opportunity to understand, discuss, challenges and opportunities and how they compare with human pharmaceutical applications.
A discussion with pharma leaders on the roadmap for early development with Tox, ADME, CMC and Phase 1 clinical design. Topics include Toxicity program for peptides, how to pick clinical dose, and preclinical to clinical translation. Panelists brought their experiences and discussed lessons learned in short presentations and a moderated roundtable.
Product and capability presentation from our sponsors
Hanna Radzey
Team Leader
Almac Group
Yvonne Angell
Executive Director, Discovery Chemistry Project Managment
WuXi TIDES
Chloe Mitchell
Field Application Scientist
Gyros Protein Technologies
Stefan Eissler
Vice President of Peptide Manufacturing Upstream
Bachem
John Phipps
Senior Director of Business Development
CPC Scientific
Charles Chase
VP Technical Business Development
Asymchem
